PDB16 COST-EFFECTIVENESS OF BLOOD PRESSURE AND URINARY ALBUMIN CONTROL IN DIABETICS WITH AN ANGIOTENSIN II RECEPTOR ANTAGONIST AND A CALCIUM CHANNEL BLOCKER- PHARMACOECONOMIC ANALYSIS OF THE MARVAL TRIAL-THE CASE OF GERMANY
Abstract
Authors
DG Smith A Gnanasakthy K Quednau